HIMS

Healthcare

Hims & Hers Health

Revenue TTMXBRL

—

Net IncomeXBRL

—

Gross MarginXBRL

—

EPS (Diluted)XBRL

—

AI-extracted key facts from press releases and SEC filings. Significance 1–10.

PartnershipBullishPer-CompanyApr 1, 2026

Hims & Hers Health Maintains Buy Rating at Canaccord Genuity Following Novo Partnership

▸Canaccord Genuity reiterates Buy rating with $30 price target
▸BofA Securities maintains Neutral rating with $23 price target
▸Platform launched access to Wegovy and Ozempic injections on March 9
▸Analysts cite long-term growth potential from GLP-1 subscription service
▸Revenue outlook faces transition challenges from compounded to branded medications

PartnershipBullishPer-CompanyMar 24, 2026

Hims & Hers renews Novo Nordisk partnership, discontinues competing weight loss products

▸Renewed partnership with Novo Nordisk to offer exclusive weight loss drugs
▸Discontinued internal competing weight loss products to focus on branded GLP-1s
▸Limited distribution of compounded GLP-1 versions following partnership renewal
▸Share price +43.7% over past month, -32.8% year-to-date
▸Trading at $22.46 with estimated fair value of $86.09

PartnershipBullishPer-CompanyMar 21, 2026

Hims & Hers restores commercial partnership with Novo Nordisk for weight-loss drug distribution

▸Novo Nordisk resumes selling weight-loss drugs via Hims & Hers platform
▸Partnership resolves prior legal conflict over copycat medication sales
▸Kathryn Beiser appointed as Chief Communications Officer to manage regulatory and investor messaging
▸Projected 2029 revenue of $3.6B and earnings of $248M
▸Strategic focus shifts toward balancing GLP-1 partnerships with broader telehealth expansion

GuidanceNeutralPer-CompanyMar 20, 2026

Hims & Hers FY26 Revenue Guidance $600M-$625M; Novo Nordisk Partnership Renewed

▸FY26 revenue guidance set at $600M–$625M
▸Novo Nordisk renewed commercial agreement for Ozempic and Wegovy access
▸Novo Nordisk litigation against Hims & Hers dismissed
▸Compounded semaglutide pill launched with $49 introductory monthly pricing
▸Analysts revised fair value estimates following Q4 results and regulatory concerns